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ABSTRACT OF THESIS

THE IMPACT OF BONE MARROW TRANSPLANTION
ON PATIENTS WITH PSYCHIATRIC DIAGNOSES:
MEDICATION ADHERENCE ASSESSMENT
We investigated whether there is a measurable difference in medication utilization
for psychiatric conditions before and after bone marrow transplantation (BMT). Previous
studies have identified a potential association between psychiatric conditions and immune
function. We hypothesized that medication utilization for psychiatric diagnoses would be
impacted by BMT. This study was a retrospective, quasi-experimental cohort design. Two
measurements of medication utilization, proportion of days covered (PDC) and medication
possession ratio (MPR) were calculated for each included Medispan-defined class of
medications before analyzing changes in PDC and MPR at the patient level. There was a
statistically significant decrease in the number of raw prescriptions as well as in PDC value
in the 2 years after BMT as compared to before the procedure. We found a decrease in
medication utilization after BMT across the measured medication classes, indicating a
potential resolution of psychiatric symptoms and a potential impact on the associated
pathophysiology. These results provide support for the premise that genetic factors
associated with immune function play a role in psychiatric illness.
KEYWORDS: bone marrow transplant, psychiatric conditions/diagnoses, psychiatric
medications, medication adherence
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Section One: Introduction
Overview
Current healthcare practices require disease states to be assessed through
objective assessments and clearly documented outcomes associated with the present
condition.1 Psychiatric conditions, however, are not assessed in this manner. Despite
4.5% of Americans suffering from a serious mental illness (equaling 11.2 million
people), patients diagnosed with mental health conditions have a higher difficulty being
able to receive treatment.2 The underlying cause of delays in receiving treatment include
lack of objective diagnostic tests, a paucity of clinical trial data due to the amount of time
required for medication trials, and the patients’ overall wellbeing adversely affecting their
ability to consistently follow treatment plans. Consequently, patients contend with
increased hospitalizations, higher likelihood of polypharmacy and a lower quality of life.
Difficulties in identifying diagnostic tools have led researchers to explore
different genetic components that may be either associated with psychiatric illnesses or
potential treatment options for these patients. Over the past decade, researchers have
utilized genetically altered mouse models in order to uncover the role of previously
understudied genes and genetic markers. Of particular note, mice that lack
the Hoxb8 gene, which was thought to be associated only with the production of
microglia during gestation, display psychiatric tendencies primarily associated with
obsessive-compulsive disorder (OCD).3 Interestingly, this behavior is reversed by bone
marrow transplantation (BMT), suggesting that there is an immune component to
psychiatric pathophysiology.4 Genome-wide associated studies (GWAS) have found
additional associations between genes expressed by the immune system and
schizophrenia. Upon further investigation, case reports have shown a similar relationship
for patients receiving allogeneic bone marrow transplantation and reduction of
psychiatric symptoms. The work presented in this thesis investigates the relationship
between the immune system and psychiatric illness through the evaluation of medication
use before and after allogeneic BMT.
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Psychiatric Conditions and Difficulty in Effectively Diagnosing and Treating
Unlike other disease states, psychiatric conditions do not have objective
laboratory measurements and standardized diagnostic tests to pinpoint a diagnosis.
Consequently, the average time between first symptoms and diagnosis is approximately
11 years.5 This delay is primarily due to the subjective nature of diagnosing psychiatric
conditions — clinicians must rely primarily on interpreting symptoms instead of proof of
a primary cause. Scoring systems are utilized in diagnosing psychiatric conditions and
consist of a review of patients’ self-reported symptoms that may or may not meet criteria
for a specific diagnosis. These scales are diverse, generally being condition-specific in
use and following different classifications depending on what governing board has
established and applied the specific scoring system’s use.6 Common scales include
Comprehensive Psychopathological Rating Scale (CPRS), Global assessment of
functioning (GAF), Major Depression Index (MDI), Positive and Negative Syndrome
Scale (PANSS), and Generalized Anxiety Disorder 7 (GAD-7).6 Without an appropriate
diagnosis, patients suffer from decreased quality of life and increased symptoms that lead
to more frequent hospitalizations and/or worse outcomes.
Primary diagnostic tools utilized for mental health patients generally follow the
international guidelines called the Diagnostic and Statistical Manual of Mental Disorders
(DSM), currently in its 5th edition.7 These guidelines outline specific psychiatric
conditions and diagnostic criteria based on the scale of common symptoms associated
with the corresponding diagnosis. This set of guidelines provides a more in-depth
analysis of symptoms for each disease state and is the primary assessment of most
psychiatric conditions. The DSM-V has been assembled by mental health specialists and
also provides updates according to what may change in current practice. The DSM is
regarded as reliable with clinicians understanding to use social sciences that may apply to
their specific patient more than those outlined in the guidelines.8
In addition to the difficulty in diagnosing patients with psychiatric conditions,
extensive time and effort is required to find effective treatment regimens. The average
period to optimize a patient’s appropriate long-term treatment is three to five years.5 This
delay is the result of the prolonged amount of time psychiatric medications require to
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reach steady-state, the myriad of adverse effects associated with these medications, and
ultimately the patient’s ability to continue therapy on their own.
Patients categorized as having a serious mental health disorder have the most
difficult time with therapy management compared to patients with other mental health
diagnoses.5 Serious mental health disorders are defined as those that are treatmentresistant or those that cause debilitating diseases including schizophrenia, obsessivecompulsive and/or other spectrum disorders.4 In fact, it was found in 2018 that only
64.1% of patients with serious mental health disorders receive treatment for their illness
and that treatment-resistant patients account for 85% of mental health associated
hospitalizations.9
This patient population struggles with normal day-to-day operations due to debilitating
symptoms that may lead to delirium, psychosis or extreme fatigue. Because of decreased
ability to focus on daily tasks, many times these patients struggle with adhering to their
medications, leading to worsening symptoms that require hospitalization or
institutionalization.
Cost is a primary concern for all aspects of care, with hospitalizations responsible
for a large component.10 In Table 1.1, the average cost and length of hospitalized stay
(LOS) for acute disease exacerbations of a variety of diagnoses are depicted.11 This data
demonstrates that patients with schizophrenia typically are subject to lengthy stays that
carry significant cost. Although cost during their hospitalizations may not be as high for
patients with mental health conditions as those with certain cancer or infectious disease
diagnoses, the average LOS was higher for schizophrenia and other serious mental health
conditions.10,12
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Table 1. 1 Hospitalization Average Length of Stay and Cost for Chronic
Conditions11

Patients with mental health disorders not only struggle with acute exacerbations,
but additionally many patients are uninsured or covered by Medicare. Table 1.2 shows
the impact of mental health diagnoses to both Medicare and other systems that provide
care to the uninsured. This data emphasizes the financial burden created by the ongoing
care of these patients and what may take place with exacerbated symptoms leading to
hospitalizations. Finding any objective biomarker for healthcare professionals would
revolutionize the diagnosis and treatment of patients with psychiatric diagnoses, resulting
in increased patient treatment success, fewer hospitalizations and decreased costs. While
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longitudinal counseling, behavioral intervention and pharmacotherapy can provide
efficacious long-term management, these treatments are not curative. Advancing our
knowledge of the underlying genetic components of mental health disorders is critical
and could lead to treatment advances that are transformative to both individual patients
and to our overburdened healthcare system.
Table 1. 2 Psychiatric Conditions and Average Cost with Associated Hospital
Length of Stay (LOS)9

Medication Use in Patients Diagnosed with Psychiatric Illnesses
Most psychiatric diagnoses require pharmacologic intervention as a major
component of therapy. Assessing a patient’s medication utilization is a method for
healthcare professionals to not only measure the patient’s adherence to their therapy but
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also evaluate the effectiveness of the medication in treating the condition.13 Appropriate
medication use, referred to as adherence, has extensive implications for patient care.
Proper medication adherence can increase a patient’s quality of life while decreasing
hospitalizations.13 In fact, non-adherence accounts for approximately 50% of treatment
failures, 25% of hospitalizations and 125,000 deaths annually.14,15
Patients with mental health illnesses struggle with medication management and
adherence to a greater extent than the general population. Table 1.3 depicts the
medication adherence percentages of common mental health conditions.16 These are
considerably lower and more variable when compared to adherence rates for common
conditions including hypertension (50-70%), congestive heart failure (40-60%), diabetes
mellitus (approximately 35%), and patients taking oral antibiotics for skin infections (5778%).17-20
Table 1. 3 Psychiatric Diagnoses and the Associated Adherence Percentages
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These lower adherence rates compared to other conditions are likely due to the
difficulties that patients with severe mental health disorders experience, such as their
inability to complete daily tasks. This statistic also emphasizes the necessity to find a way
to assist patients with mental health diagnoses in managing their diseases more
efficiently.
Nonadherence affects mental health patients in a variety of ways. One systematic
review of antipsychotic use in bipolar and schizophrenic patients summarizes results
from 38 studies consisting of 51,796 patients. The primary objective was to assess which
factors contributed to non-adherence and the degree to which each was associated. For
both bipolar and schizophrenic patients, it was found that substance abuse, cognitive
impairments, a lower level of education, poor therapeutic alliance, high intensity of
delusional symptoms, and low socioeconomic status were associated with poor
adherence. To help overcome some of these barriers, this review found that building a
personal relationship with the patient, providing more patient education and giving
assistance in overcoming substance abuse led to increases in antipsychotic adherence and
minimization in symptoms.21
In a study of 87 patients suffering from schizophrenia, overall self-reported
adherence and potential factors that impacted that adherence were examined. Of the 87
patients, adherence was reported at approximately 50% with primary reasons for lower
adherence being patients with lower insight and previous treatment-related trauma. This
assessment demonstrates what many mental health patients struggle and provides context
as to the importance of focused interventions in addition to medication therapy options.22
Similar to the study described above, meta-analysis of schizophrenic patients found that
non-adherence primarily stemmed from a lack of understanding, medication beliefs and
substance abuse. In these patient populations, this nonadherence also led to increased risk
of relapse, increased hospitalizations and suicide. 23 Patients who exhibited increased
adherence also had better relationships with their healthcare staff as well as a better
overall understanding of the medication benefits.23
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Bone Marrow Transplantation and the Impact on Mental Health
Bone marrow transplant (BMT), also known as hematopoietic stem cell
transplants (HSCT), is primarily used for the treatment of hematological malignancies.24
The process includes introducing healthy hematopoietic stem cells (usually collected
from the bone marrow) into a patient after eradication of the patient’s own bone marrow
through irradiation and chemotherapy.25 A BMT is either allogeneic or autologous.
Autologous transplants collect, purify and re-introduce the primary patient’s own cells
back into the body. Allogeneic transplants utilize donors who have matching human
leukocyte antigens (HLA), which generally may include a matched family member,
unrelated matched donor, or a family member with mismatched alleles referred to as
haploidentical (more rare and higher likelihood for post-treatment difficulties).25 The
result of an allogeneic transplant is that an entirely new immune system is established by
the donor stem cells.
BMT therapy has many complications due to its rigorous process. Regardless of
the type of BMT, this “survival treatment” includes chemotherapy, irradiation and the
long-term period of isolation in a germ-free unit. Complications can range from
neutropenia, sinusoidal obstruction syndrome (SOS), and mucositis, to graft versus host
disease (GVHD) and death. Additionally, these complications following therapy may be
acute (within 90 days) or chronic (greater than 90 days). A 2010 study found that
approximately 30% of patients survived five years after BMT. Those who did survive
five years, however, had an additional 15-year survival rate of 80%.26 Most mortality,
however, is a result of the underlying malignancy and not the BMT itself.
Because our objective was to determine whether genetic factors of the immune
system have a role in psychiatric pathophysiology, the fact that BMT can itself impact
psychiatric disorders, primarily due to trauma associated with the therapy, is a
complication of our design. One study showed that approximately 40% of BMT patients
develop a clinically significant psychopathological disorder.27 The study assessed the
process of BMT and the potential induction of mental health disorders on both nondiagnosed and previously diagnosed mental health patients due to the physical and
psychological stress that is exerted throughout the treatment. The two primary disorders
induced or exacerbated were depression and anxiety. These cases, however, were mostly
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in patients who had a relapse of their cancer following their BMT, or in those receiving
chronic prednisone therapy.27 Though the study seemed to show a large portion of
patients with this concern, further investigation revealed it to be more concentrated in a
patient population with these specific complications. Additionally, most patients resolved
from the associated symptoms within 2-3 months post-BMT, thereby not leading to the
requirement of a chronic mental health diagnosis.3
BMT has also been postulated to cause post-traumatic stress disorder (PTSD),
depression, and anxiety. In a single-center study that was conducted in 37 female patients
that were newly diagnosed with breast cancer, patients were assessed for the incidence of
anxiety, depression or PTSD, and when it occurred during their cancer progression and
treatment timeline.28 The study used a symptom assessment scale, the Profile of Mood
States (POMS), which includes multiple psychiatric conditions, though focusing on
PTSD. One group of breast cancer patients underwent BMT following chemotherapy and
was compared to a secondary group that only received chemotherapy and/or surgical
interventions. Patients underwent the evaluation at initial diagnosis, initial treatment,
recurrence of cancer (if applicable), BMT (if applicable) and at follow-up visits at 3, 6
and 12 months.28 Incidence of PTSD was comparable among groups at time of diagnosis,
and temporary phases of anxiety and/or depression were noted to occur throughout
treatment. The patients who underwent BMT did not have higher rates of any symptoms
except for a slightly elevated confusion score. Although this study had a smaller patient
population, it provides an analysis of the impact of cancer on mental health distress, and
that these outcomes are not significantly impact by BMT therapy.28
In recent years, healthcare teams have begun to assess patients’ mental health
state prior to BMT to assess their overall wellness and a patient’s ability to successfully
complete such a rigorous therapy. Many oncology teams utilize the National Cancer
Center Network (NCCN) distress thermometer (DT) prior to BMT to evaluate a patient’s
stress level and ability to cope with such a procedure. 29 In a single-center study, 50
patients were assessed for mental distress prior to their BMT therapy. These patients were
assessed using the NCCN DT, the Hospital Anxiety and Depression Scale (HADS), and
the Coordinating Rating Scale (CRS) to assess patients’ readiness for BMT. 29 This study
found that 51% of patients had a statistically significant distress level of anxiety or
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depression. The study also found that healthcare professionals underestimated the number
of patients struggling with depression and/or anxiety associated with BMT.29
Because patients diagnosed with psychiatric conditions struggle with adherence,
there is concern in whether or not patients with psychiatric diagnoses are able to
effectively complete BMT therapy. One previous study was conducted to determine what
the general effects of BMT were on patients that had a prior psychiatric diagnosis.24 The
study followed seven patients with leukemia who were also previously diagnosed with
psychiatric conditions ranging from bipolar mood disorders and autism spectrum disorder
to schizophrenia and borderline personality disorder. Of the seven patients, all were able
to complete treatment with the exception of one patient diagnosed with borderline
personality disorder. All others were able to successfully complete the BMT treatment
with little to no adverse effects related to their psychiatric illness.24 It was found that
patient comprehension, proper psychotherapy before, during and following treatment and
proper pharmacotherapy led to positive results with minimal adverse psychiatric effects.
Additional studies noted that BMT in borderline personality patients was difficult to
complete.30 Treatment failure seems to be associated with the patient’s ability to first
comprehend the treatment, but then later exhibit changes in comprehension or acceptance
of the treatment plan as their thought processes cycle between multiple personalities. The
patient’s physical and emotional wellness, however, is not typically hindered by the
process of BMT induction, treatment, or follow-up.24
In summary, BMT can provide positive outcomes for those with or without prior
psychiatric diagnoses. The BMT process induces minimal adverse effects related to
psychiatric conditions.24 As we use medication adherence measurements as a determinant
of psychiatric disorder severity and response, it is important to consider these previous
studies and characteristics of the impact of BMT itself on the mental illness.
Hoxb8, Microglia and Potential Mechanistic Explanations
Studies using mouse models have assessed a specific genetic variant that may
contribute to changes in the immune system that could be associated with psychiatric
conditions. The gene components most studied is the Hox gene group and
specifically Hoxb8 (OMIM *142963).4,31 The Hox genes primarily function to provide
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positional values in axes of the embryo, aiding in development. The protein encoded by
Hoxb8 is involved in the differentiation of myeloid progenitor cells into microglia for
functions within the brainstem.4
Microglia function as the immune cells of the brain, having multiple purposes
within the central nervous system. They act as macrophages by regulating foreign bodies
access, responding to invasive pathogens by phagocytosing and killing them, and
initiating inflammatory responses to infection and other traumatic processes.22 The
microglia also assist as dynamic contacts with synapses and may represent a stabilization
and management system for neuronal cells.4 When the number of microglia is decreased
in the brainstem, the corticostriatal circuit is affected, causing abnormalities including
frontal cortical synaptic expansion and striatal synaptic contraction. These changes lead
to problems such as excess dendritic spines, pre-and post-synaptic structural changes, and
long-term potentiation defects.32 Deficits primarily seen with structural changes to
synapses and dendritic spines involved decreased neurocognitive functioning similar to
those who suffer from Alzheimer’s disease, sever schizophrenia and/or autism spectrum
disorder.33
Mutation of Hoxb8 that inhibits functional protein production in mice induces an
OCD-like behavioral phenotype. The two primary mutations of note at this time are a
nonsense mutation of the first exon and a frameshift mutation in a premature translation
stop codon that could lead to the complete alteration or removal of Hoxb8.3 Mice that
lack Hoxb8 display uncontrollable grooming of not only the individual mouse but also of
its cage mates. This behavior is thought to be due to a potential change in cognitive
function as well as the loss of spinal cord sensory function.4 These mutant mice were
observed to spend an average of one hour less sleeping than the control group to focus on
grooming, leading to excessive hair removal and skin lesions.3 In addition to excessive
grooming, these mice also exhibited hyper-anxiety and social behavior issues. Symptoms
were difficult to resolve. In one study, knock-out mice were treated with fluoxetine, a
selective-serotonin reuptake inhibitor indicated for the treatment of depression and OCD.
The drug provided a resolution of the hyper-anxiety and social behavior issues but did not
impact the excessive grooming behavior.27 The study led investigators to hypothesize that
the absence of functional Hoxb8 was associated with obsessive compulsive behaviors.
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Through further studies of Hoxb8 deficiencies and its effect on OCD tendencies in
mice, it was found that the only way excessive grooming behaviors could be reversed is
through a bone marrow transplant from a healthy mouse.4 This adoptive transfer of
normal bone marrow to rescue Hoxb8 function and eliminate OCD tendencies shows the
potential pathologic involvement of immune function associated with OCD. Therefore, it
is hypothesized that other psychiatric conditions may also be affected by the immune
system and that a change in said function through BMT could alter psychiatric
conditions.
Since activity was noted in the central nervous system, researchers then wanted to
determine whether Hoxb8 had a role in affecting nociceptive (pain) receptors and
cognitive function in addition to the impact on behavioral.34 A study analyzed knock-out
mice that had healthy Hoxb8 removed in order to then see if both spinal cord function as
well as induced OCD tendencies would be reversed.4 They found that when
the Hoxb8 gene was removed only from the hematopoietic system, it led to excessive
grooming but no spinal cord sensory defects.4 Investigators then re-introduced healthy
Hoxb8 genes into the mice. This led to hair regrowth on the previously exhibiting
excessive grooming mice over five months, with four of the ten mice making a full
recovery and becoming indistinguishable from the wild-type mice.4
These studies help to differentiate behavioral symptoms from pain pathways and
also pinpoint the hematopoietic system as an area of intervention to improve behavioral
symptoms, but unable to restore cognitive function.4 A secondary study also reviewed
this theory and found that knock-out mice with mutated Hoxb8 showed no skeletal,
forearm clasping or dorsal root ganglia defects leading to a focus on the treatment of
behavioral changes for the mice.3 Consequently, BMT produced some positive outcomes
such as the reversal of excessive grooming behaviors. Nociceptive and spinal cord
defects, however, were not able to be reversed if observed prior to transplant.
Additionally, some researchers have hypothesized that the Hoxb8 gene is only
involved in the embryonic phase of life, with no involvement in adult species. RT-PCR
assays, however, confirmed that the Hoxb8 gene was not only expressed in embryonic
development but also in adult mice.27 In adult mice, the effects of Hoxb8 were further
analyzed through functional imaging studies to determine where in the brain may be
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associated with changes in Hoxb8. The results showed that Hoxb8 was present in the
basal ganglia and neocortex, which are primarily involved in the OCD circuit of the brain
function.3 These results associate Hoxb8 gene expression and behavior issues in mice and
suggests a potential association with human trichotillomania or OCD.
When reviewing these studies, it is valuable to understand the similarities and
differences of OCD and trichotillomania (TTM). Trichotillomania is primarily known as
repetitive hair-pulling that leads to noticeable hair loss.35 This repetition is due to an
uncontrollable urge and instant gratification associated with impulsivity, whereas OCD is
more focused on obsessive thoughts that lead to ritualistic behaviors.35 Though the two
are similar in regards to symptomatology, it was found that OCD has a much higher
incidence of lifetime disability whereas TTM may be managed over a shorter period of
time. Additionally, TTM has a lower response rate to treatment which makes the disease
more difficult to evaluate by examining medication use.35 In the studies described above,
the primary diagnosis observed in mouse models was obsessive-compulsive disorder,
although components of TTM were acknowledged and considered on the spectrum of
OCD.31
Case Reports
The studies conducted in animals described above provide compelling evidence
that genetic mutations in immune genes could be associated with psychiatric illness.
However, no controlled trials exist that address this hypothesis in humans. Data is limited
to a case series and a few case studies that provide anecdotal support. A study is being
conducted in which investigators have requested records from cases involving BMT and
coincident schizophrenia. Thus far, they have collected data for 22 patients over the
course of 15 years with schizophrenia prior to BMT that also had an autoimmune
diagnosis.36 For the patients currently included, the post-BMT results included reduced
symptoms associated with both schizophrenia and their autoimmune diseases. The
reduction of symptoms is being assessed through reviewing treatment use, which
decreased for all patients following their BMT procedure.36 This study has laid the
groundwork to assess more patients diagnosed with psychiatric conditions undergoing
BMTs and in order to evaluate its impact on long-term outcomes.
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There is little to no information regarding patients undergoing a BMT and having
reversal of symptoms associated with their psychiatric diagnosis. The only documented
incident of this phenomenon took place in 2009. A treatment-resistant schizophrenic
patient underwent a BMT to treat acute myeloid leukemia.37 Before his BMT procedure,
the patient’s treatment regimen included quetiapine, risperidone, and olanzapine. The
patient suffered from delusions and hallucinations that continued to be refractory to these
therapies. He was deemed appropriate for BMT as a part of his AML treatment and went
through 34-day isolation and had a rigorous follow-up treatment including methotrexate,
cyclosporine, and tacrolimus to help avoid GVHD.37 The patient completed the BMT and
all additional treatment with little to no complications, including no adverse impact on his
mental health status. Following his allogeneic BMT procedure, the patient no longer
required antipsychotic therapy, had a decrease in his positive and negative symptoms
scale (Positive and Negative Symptom Scale - PANSS) score, and an increase in his
score on the overall functioning scale (Global Assessment of Functioning Scale - GAF).38
Even eight years post-BMT, he still showed a resolution of symptoms with no mental
health medication or intensive treatment required.37 Figure 1.1 summarizes his psychiatric
disposition both prior and following his BMT procedure.
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Table 1. 4 Treatment from Case Report for 24-year-old Schizophrenic Patient Who
Underwent BMT37

Medications taken

PANSS -Total score16

Before BMT

After BMT

Quetiapine 800mg/day
Risperidone 12mg/day
Olanzapine 20mg/day

None

From 90-110

Interpretation

Approx. 30

Lowest: 24
(No
symptoms
present)

Highest: 168
(Extremely
severe symptoms)

Lowest: 1
(Considered
suicidal
and/or
homicidal)

Highest: 100
(Function in a
positive manner
in their daily life)

GAF - Total score17

Down to 20

Approx. up
to 95

Primary symptoms

Hallucinations
Delusions

None

There is also a case report of a patient experiencing the induction of psychiatric
symptoms following BMT. A letter to the editor of Bone Marrow Transplant describes
the case of a 67-year-old patient with no prior history of psychiatric illness who received
a BMT for the treatment of with chronic lymphocytic leukemia (CLL) and bone marrow
aplasia, requiring weekly blood transfusions.39 He received bone marrow donated by his
brother, who was clinically diagnosed with schizophrenia. Following the transplant, the
patient began to complain of frequent hallucinations, bizarre delusions and thought
broadcasting with clear consciousness. Although he had complete hematologic recovery,
he was unable to be successfully treated for his recent onset psychiatric condition.
Risperidone, citalopram, and haloperidol were all administered without success, leading
the family to provide comfort care for the patient, who was then lost to follow-up.40 The
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patient later died due to unknown causes. The primary theory that was considered in this
report was that of the adoptive transfer of schizophrenia from the brother. While
anecdotal, these cases provide evidence of a potential link between schizophrenia and
immunity.
GWAS and Potential Mechanistic Explanations
Over the past decade, researchers have begun to examine genomic data in order to
evaluate the impact of common genetic variations on human health.41 The process of
genome-wide associated study (GWAS) utilizes experimental genomic databases that
allow investigators to study the associations between single-nucleotide polymorphisms
(SNPs) and characteristics of disease.42 The prevalence of SNPs are compared between
subjects with a history of a diagnosis versus a control population to determine whether an
association exists.43
Genes are the small hereditary components that make each human unique by
comprising the chromosome. Genes are made of deoxyribonucleic acid (DNA) and
provide both structural (genotypic) and physical (phenotypic) characteristics.44 On each
chromosome, there are specific locations referred to as locus (or loci) that contain the one
or more specific genes.45 These loci are utilized as markers of specific locations,
especially when certain genetic mutations are being studied and attempted to be located
through genome mapping.45
There are multiple factors that determine the extent to which a GWAS is
successful. These factors include (1) the number of loci affecting the trait in the effected
population, (2) the distribution of these loci’s allele frequency (called genetic
architecture), (3) the sample size, (4) the genome-wide database used in the GWAS and
(5) how heterogeneous the trait and/or disease is.46 This provides context for how to
evaluate these studies, which is critical because there are extremely specific evaluations
that differ from one study to the next.
GWAS initially evaluated the genomic characterization of common conditions
including type-2 diabetes and autoimmunity, but slowly has increased to include
psychiatric conditions. The psychiatric data has now been refined into a secondary
database called the Psychiatric Genomics Consortium (PGC).47 There are over 900
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investigators from 40 countries that have contributed to the PGC network which includes
more than 400,000 human participants.48 The mental health disorders included in this
database are anxiety disorders, major depressive disorder (MDD), manic depressive
disorder (bipolar), schizophrenia, suicide attempts, and substance use disorders.
Investigators are currently expanding the PGC to also include anorexia nervosa (AN),
autism, OCD/Tourette’s syndrome and PTSD.48
The primary psychiatric diagnosis that has been reviewed through GWASs is
schizophrenia. Schizophrenia is noted to have a high heritability of approximately 6481%.47 In 2009, this was first reviewed to find 3,000 cases linked to a specific genomic
locus that then grew to include over 35,000 cases in 2014.43 This study also found 108
risk loci associated with schizophrenia that affects enhancers in the brain and immune
tissues.49 More specifically, these SNPs linked with schizophrenia were also associated
with glutamatergic transmission, calcium channels and potential changes in
immunomodulation.43 These results continue to support the likelihood that immune
function plays a specific role on psychiatric conditions, especially those affected by
cognitive function impairment—autism spectrum disorder, Alzheimer’s disease, and/or
schizophrenia.
A secondary study has identified additional gene SNPs that are enriched in
patients diagnosed with schizophrenia. A case found a cross-phenotypic link between
schizophrenia and different metabolic processes. The SNP primarily involved was
rs13107325-T and the metabolic processes included were body mass index (BMI), high
density lipoprotein (HDL) cholesterol, blood pressure and N-terminal pro b-type
natriuretic peptide in the acute coronary syndrome.49 These findings introduced the idea
that not only could schizophrenia and/or other mental health conditions may be
associated with immune function changes, but potentially metabolic function could also
be associated with mental health conditions. In addition to this specific SNP associated
with metabolic processes and schizophrenia, patients with this SNP also had an increased
likelihood to have cardiovascular disease, lung cancer and bipolar disorder, meaning that
this specific SNP could be associated with a wide variety of conditions that scientists
would have not previously associated with one another, although the association between
schizophrenia and bipolar disorder were not statistically significant.
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There are no specific genes that have been associated with being diagnosed with a
specific psychiatric condition, but more SNPs are being identified each day that may play
a role in how patients develop symptoms. The process of identifying mutations and
genetic components associated with psychiatric conditions will continue to evolve over
time, but it does provide a potential framework for future research to study more specific
genes (like Hoxb8). These GWASs could lead to additional treatment options that are
more patient specific instead of the iterative model currently being utilized to allow
mental health patients to find their optimal therapy. Additionally, these GWASs could
also lead to the discovery of new therapeutic targets which could provide better patientspecific therapies.42

Summary
These studies define a potential association between psychiatric conditions and an
immune-related mechanism that may, in turn, provide a therapeutic target for select
patients. The purpose of this thesis is to better understand the potential role of immunity
in the pathogenesis of psychiatric conditions. Although multiple theories regarding the
mechanisms of immune system influence in mental health pathology to our knowledge
medication use before and after BMT has not been studied. This connection has not been
previously reviewed using a large-scale population. We hypothesize that there is a
measurable relationship between BMT and the induction and/or reversal of psychiatric
pathology.
Our study utilized medication use and adherence as a surrogate to measure the
severity of psychiatric illness. We chose to utilize medication use, specifically through
medication possession ratios (MPR) and proportion of days covered (PDC), because it
provided an analysis of patients’ treatment over time. The reversal of psychiatric
diagnoses in patient medical records is rare, so utilizing medication use provided a
method to monitor a patients’ symptoms, rather than an objective removal of a diagnosis.
By comparing medication use before and after BMT in patient populations with
previously diagnosed psychiatric disorders, we were able to generate results that support
the scientific premise that an immune component may exist to pathologies that alter
mental health.
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Section Two: Methods
Overview
We conducted a retrospective cohort study that compared the use of psychiatric
and pain management medications used in the treatment of psychiatric diagnoses before
and after BMT. This study was classified as a quasi-experimental design due to our study
population including both those participating as well as others not participating and using
an additional medication group for overall comparison. We utilized pre-BMT and postBMT treatment timeframes and evaluated medications by medication class through
generic product identifier (GPI) and Medispan database codes. Medication classes being
reviewed include those specific to psychiatric diagnoses and pain management.
Antihypertensives were included as a non-psychiatric control class. Antihypertensive
medications were determined appropriate for our control because they are a common
medication class that manage a lifelong diagnosis with discontinuation of use being rare.
As such, two primary analysis groups were identified through generic product identifier
(GPI) codes: psychiatric and pain management medication use (exposed) and
antihypertensive medication use (unexposed). We used adherence rates, in the form of
medication possession ratios (MPR) and proportion of days covered (PDC), to evaluate
the utilization changes in each medication group to measure the effects of BMT on a
patient’s medication management of their primary diagnoses.
Study Population
Enrollees were included in this study if they were 18 years of age or older, had a
defined psychiatric disorder, received an allogeneic BMT (both matched sibling and
unmatched donors included), and filled outpatient psychiatric or pain management
prescriptions within two years before or after the BMT. Conditions studied included
bipolar/manic and major depressive disorder, obsessive-compulsive disorder, general
anxiety disorder, schizophrenia, suicide attempts, psycho-active substance abuse, opioidrelated disorders, post-traumatic stress disorder, panic disorder, alcohol-related disorder,
and movement disorders. Diagnostic codes specified by the International Classification of
Diseases, versions 9 and 10, are listed in Appendix A.48,49 Figure 2.1 provides a timeline
for data selection.
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Figure 2. 1 Timeline for Sample Selection and Eligibility Requirements

Patients were excluded from this study if they were under the age of 18, if they
received an autologous bone marrow transplant, were diagnosed with epileptic disorders
through ICD-9 or -10 codes, or if the patient had no final PDC reported following the
intervention (due to change in payer or death). Patients that received an autologous BMT
were excluded since this procedure involves harvesting the patient’s own stem cells and
then re-introducing them. Though the immune system is repaired, it still contains the
original genetic components, nullifying any potential induction or reversal of a
psychiatric condition due to a new immune system. Patients with epilepsy have
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medications that overlap with those used to treat manic depression and therefore may
skew the results.50
Data was gathered from the Truven Health MarketScan® Research Database and
included patients enrolled in health plans between January 2009 and December 2016 with
medications being reviewed if they were filled within two years before or after the BMT
index date.51 We collected medical and prescription claims through this database from
nearly 350 private payers. This database included patients that were de-identified and
anonymous. Therefore, the study did not meet the federal definition of human subjects
research, exempting it from IRB approval.52 Additionally, medication identifiers were
collected from the Medi-Span® network and utilized GPI codes for group
classifications.53 Appendix B provides specific codes used throughout the study. Figure
2.2 provides a flow diagram of the subject selection process for our patients and the
medications reviewed.
Figure 2. 2 Study Population
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Exposure and Outcomes
The quasi-experimental design provided a method to analyze and review the
utilization rates before and after BMT for our primary association medication classes and
a non-related medication class (antihypertensives). Exposed subjects were those that were
treated with prescriptions for psychiatric conditions and/or pain management while those
unexposed were classified as those with prescriptions for antihypertensive medications.
Patients with both exposed and unexposed groups are included in this study since the
primary focus was the relationship and analysis between pre- and post-BMT rather than
differences between medication classes.
The primary outcome was to compare total PDCs before and after BMT per
patient for each medication class. This analysis was completed for each medication group
including the exposed and unexposed medication groups. Furthermore, PDC ratios
(before/after and after/before) were calculated and graphed for each patient in order to
visualize overall trends and pinpoint patients that experienced either a dramatic increase
or decrease in PDC values. PDC is the recommended methodology by the Pharmacy
Quality Alliance and CMS for estimation of medication adherence for patients using
chronic medications.54
Secondary outcomes included comparison of total MPRs before and after BMT
per patient for each medication class as well as overall MPR and PDCs categorized solely
by medication class for summary statistics. MPR was not considered a primary outcome
because it does not account for a maximum adherence rate due to it being a summation of
days used rather than days covered. We decided to include it as a secondary measurement
to show the basis of what led us to utilize PDC. Although overall MPR and PDC per
medication class does not provide an accurate assessment of change per patient, it
provides a baseline review of medication change regardless of individual patients. This
initial analysis provided an understanding to warrant additional research on a per patient
level for medication classes before and after BMT.
In order to calculate a total MPR and PDC per patient, we performed a summation
of the individual MPRs and PDCs for each patient in each medication class. This
summation enabled us to calculate a more accurate total MPR and PDC than taking a
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mean value by averaging the individual medication MPRs and PDCs per patient. The
total MPRs and PDCs before and after were compared with a paired t-test.
MPR was defined as the total number of days that a medication was dispensed by
the pharmacy to each patient, divided by the patient’s total follow up time in days, up to
two years pre- and post-BMT. Furthermore, this was calculated as the difference between
the last and first prescription date plus the supplied days of the last prescription.55
Although MPR can adequately find baseline information for a patient’s medication
adherence, it does not have an appropriate maximum, resulting in the ability for
adherence to be greater than 100%. This is because MPR includes all similar medications
in the numerator, therefore having overlapping medications which may contribute to
overestimating the patient’s MPR, or adherence.
Due to this limitation, we decided to also find the PDC which accounts for this
overestimated adherence concern. Figures 2.3 and 2.4 show the equations for both
adherence measurements. PDC was defined as the proportion of days in the measurement
period “covered” by prescription claims for the same medication or another in its
therapeutic category.56 The primary difference between each analysis is that PDC only
considers days that the patient is covered during a specific time rather than a summation
of all days during the medication period. This provided a method to account for multiple
medication regimens as well as made it impossible to calculate an adherence greater than
100%.57
Figure 2. 3 Equation representing MPR57
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Figure 2. 4 Equation representing PDC57

Confounders
Allogeneic BMT is generally reserved as a secondary treatment options, for
hematologic cancers and long-term remission opportunities. For many patients, this
means that they are generally more ill than our general population and may have multiple
chronic conditions. This can lead to decreased quality of life, increased polypharmacy,
and increased medication use. Consequently, the disease burden was determined using
the Charlson Comorbidity Index score and individual components that were then
reviewed as our primary descriptive characteristics.58 Of note, subject characteristics
including sex, gender, and age, were not identified through Truven’s database and are
discussed further in the limitations section later in this paper.
An acceptable percentage for adherence in most chronic disease states is generally
around 0.8 (80%).59 Those with major psychiatric diagnoses, however, suffer from
debilitating illness and a lack of motivation due to adverse effects and impaired cognitive
function, leading to a decreased adherence approximately being 0.5-0.6 (50-60%) with
certain conditions, like schizophrenia, having an adherence of approximately 0.35
(35%).60 Consequently, we considered ≥ 0.5 (50%) to be an adherent patient for our study
while those < 0.2 (20%) being considered as having a low adherence (potentially
considered a discontinuation of the medication) when assessing their final PDC and MPR
values.

Statistical Analysis
Descriptive statistics were determined for patient comorbidities using the
Charlson Comorbidities Index and frequencies were assessed for these conditions among
the population. Summary statistics were calculated for each medication class. The

24

difference in overall number of prescriptions was examined. Additionally, the mean
MPRs and PDCs before and after BMT per medication class were also determined and
included in summary statistics.
Analysis of the total PDCs and MPRs per patient for each medication class before
and after BMT was conducted using paired t-tests. Confidence intervals were also
reported for MPR and PDC for each medication class per patient. These 95% confidence
intervals are defined as the range that the actual mean value lies within 95% confidence
and at a statistical significance level of 0.05. Q-Q plots were used to asses normal
distribution. Bivariable analyses used non-parametric testing strategies such as the
Kruskall-Wallis test to measure the effect of each adherence variable comparing results
before and after each patient’s BMT. The Dunn test was utilized to account for multiple
comparisons for values of statistical significance.
A two-tailed analysis and paired t-tests were completed with statistical
significance defined at a p-value < 0.05. All data analysis was completed using SPSS
Version 26.0.61 This study’s data represents proprietary information used for research by
the Institute for Pharmaceutical Outcomes and Policy at the University of Kentucky
College of Pharmacy.
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Section Three: Results
Study Population
The study population that was obtained through the Truven Health MarketScan®
Research Database and the method used to apply inclusion criteria are depicted in Figure
3.1. The final group for analysis included 8,233 patients who had a psychiatric diagnosis,
underwent BMT, and received medication for treatment of a psychiatric condition within
2 years. The number of prescriptions for the treatment of each condition, along with the
number of prescriptions for antihypertensives in these patients, are listed below.
Figure 3. 1 Subject Selection Process
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Figure 3.1 Subject Selection Process (Continued)

In addition to the prescriptions patients received, we also assessed the frequency
and percentages of comorbidities for our patient population through analysis of Charlson
Comorbidity Index in Medispan. These results are listed in Table 3.1. This table reflected
what was anticipated to be the most likely comorbidity in the patient population (cancer).
It was surprising, however, that more patients than 81.6% did not have a cancer diagnosis
since BMT is generally only utilized post-chemotherapy associated with cancer.
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Table 3. 1 Comorbidities Frequencies and Percentages

Descriptive Analysis
To determine the effect of BMT on psychiatric medication utilization, medication
adherence PDC was used as a primary outcome, with MPR used as a secondary outcome.
Both MPR and PDC were included because they each are associated with different
limitations.
MPR was calculated by taking the sum of all medication days’ supply filled
divided by the total days in the period. As discussed in the Methods section, this may
skew the results to overestimate the MPR and ultimately, a patient’s adherence rate, due
to the fact that there is not a maximum number for the ratio when patients receive
multiple medications for the treatment of a diagnosis. In order to minimize
overestimation, MPRs included in this study were limited to a maximum ratio of 5.62
PDC, however, eliminates this issue by having a natural maximum of one. PDC measures
the portion of days covered in a given time period by at least 1 medication to treat that

28

diagnosis rather than a total days supplied of all medications that may have overlapped
for that same period.
The changes in total before and after prescription count per medication class were
calculated for the data sets. The number of prescriptions received by patients, grouped by
medication class, are presented in Table 3.2 (MPR) and Table 3.3 (PDC).
Table 3. 2 Number of Prescriptions Prior and Following BMT Used for MPR
Calculations
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Table 3. 3 Number of Prescriptions Prior and Following BMT Used for PDC
Calculations

This data demonstrates that the total number of prescriptions in each medication
class analyzed decreased after BMT in our patient cohort. ADHD medications,
benzodiazepines and hypnotics/sedatives had the greatest decreases in overall
prescriptions after BMT with mean decreases of 42%, 33% and 38% respectively.
Between the two tables, the total prescription count is higher in each medication class for
the MPR data since each medication is counted regardless of prescription overlap
whereas for PDC overlapping prescriptions count as one.
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Univariate and Bivariate Analyses
Table 3.4 depicts the overall change in mean MPRs calculated for each drug class
before and after BMTs. This data is graphically represented in Figure 3.2.
Figure 3. 2 Summary Statistics of Pre- and Post-BMT in Mean MPR
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Table 3. 4 Pre- and Post-BMT in Mean MPR

Overall, the MPR values ranged from 0.17 to 0.55 with antidepressant
medications having the largest raw difference, decreasing by 0.124. Opioids had the
greatest percent change between pre- and post-BMT MPR at -31.6% with a raw
difference of 0.103. Each medication class exhibited an overall decrease in MPR after the
BMT compared to pre-BMT values.
MPR was also calculated for each medication class for each individual patient.
Table 3.4 identifies trends in the overall medication class while this analysis highlights
the changes at the individual patient level. This calculated data included evaluating the
change in total MPR before and after BMT. In order to determine the statistical
significance of these changes, a paired t-test was conducted since each patient had a
before and after value to directly compare. Table 3.5 depict these results. All decreases in
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MPR were statistically significant (p < 0.05) with all but antipsychotics being highly
statistically significant (p < 0.001).

Table 3. 5 Bivariate analysis with MPR per patient grouped by medication class as
the outcome of interest

Figure 3.3 and Table 3.6 present mean PDC values pre- and post-BMT grouped
by medication class while Table 3.7 contains the pertinent results of bivariate analysis of
the PDC data analyzed for individual patients.
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Figure 3. 3 Summary Statistics of Pre- and Post-BMT in Mean MPR
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Overall, the PDC values were approximately 50% lower than the corresponding
MPR value resulting in a range from 0.12 to 0.27. Similar to MPR, across each
medication class, the PDC values decreased post-BMT with antidepressants again having
the largest raw difference. Opioids, however, had the largest percentage decrease.
Though the raw PDC values are lower than the corresponding MPR values truncating the
raw difference between post- and pre-BMT values, the percent decrease in PDC values
mirrors that of the MPR values. Of note, antihypertensive medications had the smallest
percent change for both MPRs and PDCs.
The PDC values for each medication class when calculated on a per patient basis
are listed in Table 3.7. P values as calculated using paired t tests, along with 95%
confidence intervals, are included.
Table 3. 7 Bivariate analysis with PDC per patient grouped by medication class as
the outcome of interest
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Results for PDC per patient paralleled those from PDC of overall medication
class. The differences were that overall fewer prescriptions were analyzed for the per
patient group and the overall decreases were more dramatic.
Overall, the results presented show that MPR values provide slightly higher
adherence rates as compared to PDC values for medication class. This is due to the
number of prescriptions included as well as the ratio having a maximum of 5 (500%) for
MPR as compared to PDC’s maximum being 1 (100%). Although there is a difference in
the adherence overall, both groups showed a reduction in prescriptions and adherence for
each medication class. These results were all statistically significant except for
anticonvulsant medications reviewed with PDC.

Event analysis for Future Studies
Figures 3.4 through 3.43 provide a visualization for the change in medication
utilization for each patient before and after BMT. These scatter plots depict the spectrum
of adherence and highlights potential outliers that may be of interest for future
prospective and randomized controlled trials. To create these plots, the ratio of post-BMT
and pre-BMT PDC or MPR for each patient were plotted on a linear scale. These plots
were included to be able to highlight the spectrum of change amongst the patients in
order to reveal potential outliers. The before/after plots highlight those patients that
experienced an above average decrease in MPR or PDC, while the after/before plots
highlight patients with an above average increase in MPR and PDC. These plots provide
evidence that there are individual patients that experienced dramatic increased or
decreased need for a specific class of medication.
Figures 3.4 through 3.23 depict MPR change comparing patients with a decrease
in medication use after compared to before BMT (Before:After) and those with an
increase in medication use after compared to before BMT (After:Before). Table 3.8
shows those with the largest decrease or increase (greater than 5) for MPR.
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Figure 3. 4 and Figure 3. 5 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for ADHD MedicationsFigure 3. 6 and
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Figure 3. 7 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Anti-anxiety Medications

Figure 3. 8 and Figure 3. 9 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Anticonvulsant Medications
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Figure 3. 10 and Figure 3. 11 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Antidepressant Medications

Figure 3. 12 and Figure 3. 13 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Antipsychotic Medications
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Figure 3. 14 and Figure 3. 15 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Benzodiazepine Medications

Figure 3. 16 and Figure 3. 17 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Hypnotic/Sedative Medications
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Figure 3. 18 and Figure 3. 19 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Migraine Medications

Figure 3. 20 and Figure 3. 21 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Opioid Medications
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Figure 3. 22 and Figure 3. 23 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Antihypertensive Medications

Table 3. 8 Percentages of the Change of PDC Sums with Ratio Greater Than 5

Each scatterplot assessed the sum difference of MPR per patient organized by
medication class. All medication classes contained outliers with ratios greater than 5 with
those having a decrease after BMT (Before:After) having more outliers with a larger
range of differences. This provides a visual depiction of specific outliers that could reflect
potential change in psychiatric diagnoses due to a complete decrease in medication use.
Figures 3.24 through 3.43 depict PDC change comparing patients with a decrease
in medication use after compared to before BMT (Before:After) and those with an
increase in medication use after compared to before BMT (After:Before). Table 3.8 lists
the percentages of each patients group with a decrease or increase (greater than 5) for
PDC.
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Figure 3. 24 and Figure 3. 25 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for ADHD Medications
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`

Figure 3. 26 and Figure 3. 27 Scatter Plot of Pre- and Post-BMT PDC Sums per Patient for Anti-anxiety Medications

Figure 3. 28 and Figure 3. 29 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Anticonvulsant Medications
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`

Figure 3. 30 and Figure 3. 31 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Antidepressant Medications

Figure 3. 32 and Figure 3. 33 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Antipsychotic Medications
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`

Figure 3. 34 and Figure 3. 35 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Benzodiazepine Medications

Figure 3. 36 and Figure 3. 37 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Hypnotic/Sedative Medications
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`

Figure 3. 38 and Figure 3. 39 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Migraine Medications

Figure 3. 40 and Figure 3. 41 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Opioid Medications
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`

Figure 3. 42 and Figure 3. 43 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Antihypertensive Medications

Table 3. 9 Percentages of the Change of PDC Sums with Ration Greater Than 5

Each scatterplot assessed the sum difference of PDC per patient organized by
medication class. All medication classes contained outliers with ratios greater than 5 with
those having a decrease after BMT (Before:After) having more outliers with a larger
range of differences. This provides a visual depiction of specific outliers that could reflect
potential change in psychiatric diagnoses due to a complete decrease in medication use.

Section Four: Discussion
Overview
This study is the first to analyze changes in psychiatric condition severity after
patients undergo BMT. Medication adherence and the amount of medication needed were
utilized to examine this potential relationship. Decreases in patient medication
requirements after a BMT procedure may signify a resolution of psychiatric symptoms
associated with a given diagnosis. Our results provide evidence suggesting that a reversal
of psychiatric pathology occurs in some patients as a result of alteration of their immune
system through BMT. This study provides novel insights concerning the potential impact
BMT has on patients with psychiatric conditions while also providing evidence that
supports the scientific premise encouraging further research in order to solidify the
connection between immunologic mechanisms and long-term patient progression.
Event Analysis
Overall, the descriptive statistics show a consistency in the reduction in the
number of prescriptions required after BMT compared to before the procedure. Though
this decrease does not explicitly reflect any change in patients’ psychiatric diagnoses, it
does provide evidence that BMT has a general effect of lowering the overall number of
prescriptions a patient requires—an indication of a potential reduction or resolution of
psychiatric symptoms or comorbidities. The comorbidity frequencies reflect the expected
distribution for our patient population. The majority of the patients included in the
analysis had a recorded diagnosis of cancer, which is the primary indication for BMT.
These comorbidity statistics reflect that the patient population analyzed is a valid sample
to investigate the impact of BMT. For comparative note, there is no specific Charlson
code for hypertension—the indication for our reference drug class. Therefore, there was
no way to determine the frequency of hypertension diagnosis in our study population.
The frequency of prescriptions of antihypertensives, however, was similar to expected
estimates produced by general prevalence statistics.
Although the number of prescriptions were more numerous than initially
anticipated, it decreased significantly when they were matched and examined at the
individual patient level. This decrease in prescription count could be the result of frequent
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hospitalizations that are not accounted for in the Truven database. This issue is discussed
further in the limitations section below.
As for overall MPR and PDC, we were able to document decreases in both values
for each medication class, prompting our individual patient analyses. Of note, due to
MPR having an overlap in medication use and not accounting for patients filling
prescriptions close to their index date, the MPR analysis and data is still inflated due to a
maximum possible ratio up to 5 (500% adherence). Though the raw numbers are more
inflated, the before and after differences in MPR provide insight into the overall trends in
the medication classes. MPR per patient categorized by medication class characterized a
major decrease in use from before to after BMT. The MPR data revealed a statistically
significant decrease in utilization for all medications, including our control group of
antihypertensives showing a potential that cardiovascular conditions may also have a
decrease in medication utilization following BMT.
PDC per patient was our primary endpoint. Overall, all medication classes had
both a statistically significant decrease in mean PDC and in the total number of
prescriptions after BMT, except for anticonvulsant, antipsychotics and migraine
medications. When drawing conclusions from this data, statistical versus clinical
significance must be considered when comparing each medication class due to our large
sample size. Some considerations for future subgroup analyses include studies focusing
on specific locations to be able to analyze a smaller patient population to better assess the
clinical impact.
This study found that all medication classes examined had reduced use after BMT
compared to before the procedure. Even medication classes with small decreases in use
were noted to be statistically significant, and therefore these differences may not reflect
clinical significance. Due to the large number of prescriptions and patients analyzed, even
small decreases in utilization and adherence were highly statistically significant. In order
to determine clinical significance, more detailed analysis of individual patients that had
extreme changes in medication use, as reflected in the upper regions of the respective
scatter plots, could be performed. Through further review, statistical versus clinical
significance should be considered, as investigation of additional confounders could be
accounted for in order to produce a more accurate assessment and improve our ability to
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gauge the clinical significance of the results.
Secondary analyses included in the study were the MPR per patient and PDC per
patient scatter plots that measured the difference ratio of after to before medication use
for each patient. These plots were included to highlight the spectrum of change amongst
the patients in order to reveal potential outliers. The before/after plots highlight those
patients that experienced major decreases in MPR or PDC while the after/before plots
highlight patients with major increase in MPR or PDC. These plots demonstrate that there
were individual patients that had dramatic decrease or increase in medication
requirements for specific medication classes. These dramatic changes in MPR and PDC
signify that a subpopulation of patients had resolution of symptoms and a reversal of a
psychiatric illness. The percentage of patients that were included in the extreme group of
a decreased need for medication was consistently higher than the percentage that
experienced an extreme increase in medication use (Table 3.9). This is consistent with
our hypothesis that psychiatric pathology is partly driven by genetic alterations of the
immune response. It stands to reason that, because all patients included in the analysis
had a pre-existing psychiatric diagnosis, if polymorphisms associated with immune genes
contribute to this pathology, the balance of overall medication use would be shifted
downward.
This indicates that there is a need for more research to be completed, either through
randomized controlled trials or prospective analysis. These potential studies would
provide additional insight into the relationship between the immune system and
psychiatric pathology driven by genetic factors. This initial medication analysis only
provides an overview of an association between BMT and psychiatric diagnoses.
Prospective patient tracking would enable more detailed follow up with the ability to
monitor changes in patient diagnoses directly.
Our control medication class, antihypertensives, had similar results to the
medication classes of interest. It is noteworthy that the antihypertensive class had the
smallest percentage change for overall MPR and PDC, as well as PDC calculated on a per
patient basis. This could mean that although the decrease in antihypertensives required
post BMT was statistically different, the change in medication requirement induced by
BMT was minor comparatively speaking. Alternatively, a previously identified link
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between schizophrenia and hypertension could account for this result. In the
schizophrenia GWAS study discussed previously, patients diagnosed with schizophrenia
that carried polymorphisms in a specific gene locus were found to also have an
association to an adverse effect on cardiovascular health.49 This analysis is still being
conducted, but could provide further correlation of the unknown effects of our immune
system and the role it plays in multiple diseases including psychiatric and cardiovascular
illness.

Strengths
Most research has focused on mouse models or GWAS studies gathering baseline
knowledge rather than applying it to clinical practice. Additional information is focused
on humans through case reports rather than specific analysis of patient factors. This
project is the first study to explore the impact of BMT on psychiatric conditions at the
patient population level using medication adherence and utilization analysis. This study is
a first attempt at systematically connecting BMT to psychiatric condition resolution/onset
in a human population. Previous reports focus on anecdotal evidence on a case-by-case
basis. This study provides the first population analysis associating BMT with decreases in
psychiatric medication use and adherence.
This study design of reviewing medication adherence is also one that has not been
utilized in the past in regard to this patient population. Medication use, although it may
not encompass the overall impact of BMT on the changes in psychiatric disease severity
or progression, provides a baseline analysis for how treatment of these conditions is
impacted. The study provided an overall understanding of the changes in therapy for
patients adjusting to medication requirements after BMT therapy, and the potential
change in psychiatric symptoms and/or diagnoses—providing an impetus for further
investigation. The overall decrease in medication use reveals that BMT has at a minimum
an impact on prescription number and medication requirement while still prompting
further investigation into the effect it has on actual diagnostic outcomes.
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Limitations
With regard to descriptive statistics, our data did not include age, sex or ethnicity
of the patients analyzed in this cohort. Utilizing this information could have helped to
provide secondary analysis that may lead to certain patient characteristics having an
association with medication use reduction. In future studies, this information could also
be analyzed and provide additional data that may pertain to the direct impact of BMT on
psychiatric conditions depending on patient factors rather than medication use.
With both MPR and PDC, adjustments in a patient’s dose was unaccounted for in
this study. For patients with mental health conditions, both individual therapies and
medications dosage may be adjusted frequently since psychiatric diagnoses generally
require frequent alterations to optimize the appropriate individualized therapy. Although
medications within the same drug class and the number of days that a medication was
prescribed were accounted for through this study, an individual’s dosage adjustments
were not. This means that a discontinuation of a specific dose to switch to a different
dose would be a change in therapy that is not captured as impacting our overall analysis.
Analysis based on medication doses could be utilized in future studies in to order to
provide a more complete picture.
Medications utilized for treating psychiatric conditions may also be used for
similar comorbidities. For instance, we decided to exclude patients with epileptic
diagnoses that were originally included in our analysis. Some medications used for
epilepsy, like valproate and lamotrigine, were still included due to their therapeutic use
for bipolar/manic depression. However, if patients also had epilepsy that was not
formerly diagnosed, these medications could be used for that additional treatment.
Therefore, though treatment changes may have been due to a change in a comorbid
condition, those changes were captured as if they were due to a change in treatment for
the psychiatric diagnosis.
Acute care prescriptions used while patients were hospitalized were not assessed
or analyzed because this data was not available in the databases utilized. Because of the
multiple comorbidities within our study population, and because of the high likelihood of
hospitalization in a subset of patients for the treatment of their psychiatric conditions,
periods of hospitalization likely significantly impacted both PDC and MPR results. These
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unaccounted hospitalizations could also help explain why the overall adherence rates
were fairly low, even prior to BMTs. A way to account for this would be through
hospital-specific studies that would include in-patient medications for analysis rather than
relying solely on outpatient prescriptions.
A patients’ overall wellbeing and the drastic change that takes place before and
after BMT could also be a potential reason for the decrease in medication use. Patients
requiring this “survival treatment” may also require an extensive medication regimen due
to the potential illness and comorbidities being treated prior to BMT. The decrease in all
medications could coincide with a patient’s improvement in overall health and quality of
life, thereby minimizing medication use due to becoming healthier rather than being a
direct effect of BMT therapy.
Furthermore, many patients with psychiatric conditions are unable to maintain a
steady income. In 2006, it was found that 37% of working-age adults with severe mental
illness were uninsured for at least part of the year.63 Additionally in 2010, approximately
33% of adults on Medicaid met the criteria for having a psychiatric condition.63 Patients
were only included in this study if they had private insurance, which was gathered
through our data collected from Truven Health MarketScan® Research Database.51 This
limitation leaves a substantial portion of patients unaccounted for in our population, due
to their inability to enroll in private insurance. This means that our results only include a
portion of our population, rather than an adequate representation of patients with
psychiatric diagnoses that could be further analyzed in future studies.
Future Opportunities
This project provides a baseline understanding of whether or not there are changes
to psychiatric illness secondary to BMT with plenty of opportunity for expansion. An
additional model may include case studies reviewing patients previously diagnosed with
psychiatric conditions undergoing BMT and the potential long-term effects that took
place as a result. The previously mentioned study with only seven patients is the only
case study article addressing this issue at this time. Prospective studies should be
designed to investigate changes in diagnosis and/or symptoms of psychiatric conditions
for patients undergoing BMT. However, prospective studies in humans are fraught with
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difficulties, including those that are conducted in the challenging population of patients
with psychiatric conditions. Our data provides additional evidence of a link between
immunity and psychiatric illness, and therefore future clinical studies are warranted, as
most of this work has been in animal models.
In addition to medications, investigators could also consider examining patient
assessment scores and the changes before and after BMT. These could include PANSS
and GAF that were utilized in a case report above as well as Daily Assessment
of Symptoms – Anxiety, Generalized Anxiety Disorder 7 (GAD-7), Hamilton
Anxiety Scale (HAM-A), Panic and Agoraphobia Scale (PAS) and others.17 These
diverse scales provide different ways to assess symptom management that may not be
addressed through medication utilization. Medication utilization only directly provides
information regarding changes in therapy while these scoring systems measure patients’
symptoms. These could be used in the future to generate additional support for the link as
well as provide an explicit link between BMT and resolution of psychiatric conditions.

Conclusions
Overall, the results indicate a statistically significant decrease in both the number
and adherence of psychiatric/pain management medications as well as antihypertensive
medications as a result of BMT. These decreases reveal that BMT may play a role in
positively influencing psychiatric diagnoses as well as chronic pain and cardiovascular
conditions. These decreases in medication therapy provide the opportunity to pursue
further investigation into the impact of BMT through assessment scores in order to
directly track patient symptoms. Though these results are all statistically significant, the
clinical significance is inconclusive as the large sample sizes may have been the
underlying driver for statistical significance of most primary endpoints. Further
investigation is required to verify the clinical significance. This study effectively shows
that across all of the observed medication classes, medication therapy decreases post
BMT. This decrease may be attributed to unexplored immune system links to psychiatric
conditions and/or the effectiveness of BMT increasing overall wellbeing. The interplay
between BMT and psychiatric diagnoses is not well understood at this time. Mouse
models and GWAS studies have shown a potential link. This study is the first step in
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exploring this association in a human population. There is a need to further investigate
the long-term effects in this patient population with regard to change in psychiatric
conditions after BMT. Treatment of major psychiatric conditions could be revolutionized
by BMT if this connection is verified.
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Appendices
Appendix A: ICD 9 and 10 Diagnostic Codes for Psychiatric Conditions and BMT

Disease State

ICD-9 CM

ICD-10 CM

Bone Marrow Transplant

V42.81

Z94.81

Encounter for general psychiatric

V70.1

Z04.6

Schizophrenia

295.x

F90.x

Suicide Attempt

E950.x

T14.91

Psycho-active Substance Abuse

305.x

F19.x

Opioid-Related Disorders

304.x

F11.x

Bipolar, Manic Depressive and Major 296.x

F33.x

examination, requested by authority

Depressive Disorders: recurrent
events
Bipolar, Manic Depressive and Major 311.x

F32.x

Depressive Disorders: single events
Post-traumatic Stress Disorder

309.81

F43.12

Obsessive-Compulsive Disorder

301.4

R46.81

Generalized Anxiety Disorder

300.02

F41.1

Panic Disorder

300.01

F41.0

Alcohol-Related Disorders

291.x

F10.x

Movement Disorder: stuttering,

307.x

F95.x

Tourette’s, psychogenic pain
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Appendix B: Medication Classes and GPI Codes Indicated for Psychiatric Conditions and
Control Medications (antihypertensives)

ADHD Medications
Root Classification

Secondary Classification

Medispan Codes

Adhd/anti-narcolepsy/anti-

Appetite Suppressants

55175x

Decongestants/Appetite

99933x, 41100x,

Suppressants

11926x, 537x

Stimulants

99806x, 65162x,

obesity

54092x, 719x, 591x
Sympathomimetic amines

63187x, 57664x,
55289x, 54569x,
677x, 527x

Wakefulness promoting agents

63459x

Antianxiety Agents
Root Classification

Secondary Classification Medispan Codes

Antianxiety Agents

57866x, 57480x, 55175x,
54124x, 53506x
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Anticonvulsant Agents
Root Classification

Secondary Classification

Neuromuscular Agents, Anticonvulsants, mood
Anticonvulsants, Mood
Stabilizers

Medispan Codes
51672x, 43353x

stabilizers
Anticonvulsants/Restless Legs

68387x, 66105x, 65162x,

Syndrome

55048x, 55045x, 33261x,
21695x, 16590x

Antiepileptic

76282x, 51079x, 13668x

Barbiturate anticonvulsants,

65162x

mood stabilizers
Sulfamate-substituted

43063x

monosaccharide
anticonvulsants

Antidepressants
Root Classification

Secondary Classification

Medispan Codes

Antidepressants

Seasonal affective

63739x, 58016x, 54569x

SNRIs

68382x. 68788x,
62584x, 63874x,
61392x, 18837x,
33261x, 53002x,
51672x, 33261x.
21695x, 21695x
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Antidepressants
Root Classification

Secondary Classification

Medispan Codes

SSRIs

71335x, 63629x,
62584x, 60429x,
16590x, 58016x,
55700x, 54868x,
47463x, 35356x, 23155x

Tricyclic antidepressants

406x, 536x, 603x,
61392x, 54274x

Antipsychotics
Root Classification

Secondary Classification

Antipsychotics/Antimanic Antimanic
Agent

Medispan Codes
143x

Atypical Antipsychotics

99746x, 76282x,
68001x, 67544x,
66105x, 60505x,
49999x, 49848x

Phenothiazines

51079x, 904x, 725x,
719x, 536x, 378x

Typical Antipsychotics
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99919x

Benzodiazepines
Root Classification

Secondary Classification

Medispan Codes

Benzodiazepines

58016x, 50752x, 904x,
839x, 603x, 403x, 54x,
24x

Hypnotics/Sedatives
Root Classification

Secondary Classification

Medispan
Codes

Hypnotics/Sedatives/Sleep

Imidazopyridines

67544x, 55887x,

Disorders

43063x,
Other

49999x, 41163x,
701x, 677x,
363x, 157x

Migraine Medications

Migraine Products

Ergot alkaloids

52054x

Sympathomimetic drug

62584x

Triptan/Serotonin Receptor

63801x, 62208x,

agonists

540279x, 6026x,4923x,
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Opioids
Root Classification

Secondary Classification

Medispan Codes

Analgesics

Opioids

99850x, 67457x, 66336x,
65243x, 63629x, 42358x,
57866x, 55887x, 55700x,
55175x, 54868x, 54274x,
65162x, 52959x, 43386x,
33358x, 16590x, 10544x

Antihypertensives (Control)
Root Classification

Secondary Classification

Medispan Codes

Antihypertensives

ACE inhibitors

74x, 603x, 904x, 13811x,
21695x, 31722x, 52427x,
50090x, 51285x, 55045x,
58118x,60760x, 62584x,
66336x, 67544x, 68788x,
71335x

alpha-Agonist

38779x

ARB inhibitors

42291x, 42658x, 54569x,
62332x

CCBs

70934x, 55289x, 54868x,
54124x, 51138x, 43547xl
43353x, 16590x

Combination (ARB and Thiazide 228x, 781x, 52343x, 55700x
Diuretics)
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Antihypertensives (Control)
Root Classification

Secondary Classification

Medispan Codes

Combination (Beta Blocker and

378x, 52555x

Thiazide Diuretics)
Vasodilators

349x, 64380x
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